In addition to metformin, the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide has been shown to suppress breast cancer cell activity and increase mRNA levels of adiponectin and its receptors in obesity-associated breast cancer [30]. This evidence concerns the gene ADIPOQ and obesity due to melanocortin 4 receptor deficiency.